Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan

Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan

Tomoki Nakamura, Kunihiro Asanuma, Tomohito Hagi, Akihiro Sudo Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, JapanCorrespondence: Tomoki Nakamura Department of Orthopaedic SurgeryMie University Graduate School of Medicine, Tsu, Mie, JapanTel +81-592315022Fax +81...

Full description

Bibliographic Details
Main Authors:	Nakamura T, Asanuma K, Hagi T, Sudo A
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-10-01
Series:	Drug Design, Development and Therapy
Subjects:	soft tissue sarcoma eribulin pazopanib trabectedin efficacy overall survival
Online Access:	https://www.dovepress.com/clinical-outcome-of-systemic-treatment-for-advanced-soft-tissue-sarcom-peer-reviewed-article-DDDT

Similar Items

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
by: Eijiro Shimada, et al.
Published: (2021-10-01)

The value of trabectedin in the treatment of soft tissue sarcoma
by: Nakamura T, et al.
Published: (2016-01-01)

Recent Advances in the Treatment of Metastatic Soft Tissue Sarcoma
by: Elizabeth J. Davis, et al.
Published: (2018-12-01)

Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG)
by: Bernd Kasper, et al.
Published: (2015-01-01)

The Role of Trabectedin in Soft Tissue Sarcoma
by: Tomoki Nakamura, et al.
Published: (2022-02-01)

Pazopanib in the management of advanced soft tissue sarcomas
by: Cranmer LD, et al.
Published: (2016-06-01)

Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
by: Desar IME, et al.
Published: (2016-08-01)

Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study
by: Akira Kawai, et al.
Published: (2022-05-01)

Key Advances in the Systemic Therapy for Soft tissue Sarcomas: Current Status and Future Directions
by: Neelesh Soman, et al.
Published: (2013-10-01)

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma
by: Lorena Landuzzi, et al.
Published: (2023-07-01)

Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells
by: Mauro Loi, et al.
Published: (2022-11-01)

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group
by: Emanuela Palmerini, et al.
Published: (2021-03-01)

Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature
by: Yoshiro Nakahara, et al.
Published: (2017-04-01)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
by: Que Y, et al.
Published: (2018-07-01)

Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
by: Anthony D. Ho, et al.
Published: (2010-10-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01)

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
by: Marie-Sophie Minot-This, et al.
Published: (2022-06-01)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
by: Axel Le Cesne, et al.
Published: (2019-08-01)

Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?
by: Tomoki Nakamura, et al.
Published: (2022-10-01)

Trabectedin in Soft Tissue Sarcomas
by: Bradley J. Petek, et al.
Published: (2015-02-01)

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
by: Sang Kyum Kim, et al.
Published: (2021-03-01)

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
by: William L. Read, et al.
Published: (2016-10-01)

The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin
by: Gerlinde Egerer, et al.
Published: (2009-07-01)

Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region
by: Nour Abdul Halim, et al.
Published: (2021-01-01)

Efficacy of Eribulin in Soft Tissue Sarcomas
by: Edward Phillips, et al.
Published: (2022-03-01)

CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS
by: P. V. Мazin, et al.
Published: (2017-05-01)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
by: Audrey Laroche, et al.
Published: (2017-04-01)

Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
by: Nadia Hindi, et al.
Published: (2020-12-01)

Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review
by: Francesco Pierantoni, et al.
Published: (2019-07-01)

Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study
by: Tomohiro Fujiwara, et al.
Published: (2022-08-01)

Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin
by: Alexandre de Nonneville, et al.
Published: (2019-03-01)

A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients’ Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece
by: Stefania Kokkali, et al.
Published: (2022-04-01)

Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma
by: Yasuyoshi Sato, et al.
Published: (2021-12-01)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
by: María López-Álvarez, et al.
Published: (2022-12-01)

Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13)
by: Bernd Kasper, et al.
Published: (2024-01-01)

The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature
by: Fotopoulos George, et al.
Published: (2015-09-01)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
by: Steven Attia, et al.
Published: (2023-10-01)

<i>CUL4A</i>, <i>ERCC5</i>, and <i>ERCC1</i> as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study
by: David S. Moura, et al.
Published: (2020-04-01)

Actual long-term survival after resection of stage III soft tissue sarcoma
by: Do Weon Lee, et al.
Published: (2021-01-01)

Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin
by: Chiara Fabbroni, et al.
Published: (2021-03-01)